<DOC>
	<DOCNO>NCT01725126</DOCNO>
	<brief_summary>This study first administration GSK2890457 human . The study conduct 3 part : - Part A ( conduct single investigative site ) determine safety tolerability GSK2890457 alone healthy subject six week dose , well evaluate potential pharmacokinetic interaction metformin . Part A consists Screening , Treatment ( 6 week ) Follow-up period . - Part B ( conduct multiple site ) determine safety , tolerability , pharmacodynamics ( PD ) subject Type 2 diabetes ( T2D ) co-dosed six week liraglutide ( Victoza ) . Part B consist Screening , Run-in ( 1 week ) , Stabilization ( 12 week ) , Treatment ( 6 week ) Follow-up period . - Part C ( conduct multiple site ) determine safety , tolerability , PD subject T2D co-dosed 6 week metformin . Part C consist Screening , Run-in ( 1 week ) , Stabilization ( 12 week ) , Treatment ( 6 week ) Follow-up period .</brief_summary>
	<brief_title>To Investigate Safety , Tolerability Pharmacodynamics GSK2890457 Healthy Volunteers Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Part A ( Healthy Subjects ) Subject able understand voluntarily provide consent participate study 18 70 year age , inclusive , time signing informed consent Body Mass Index ( BMI ) 18.0 35.0 Kilogram ( kg ) per m^2 , inclusive Understands willing , able likely compliant take study drug comply study procedure restriction Subject willing consume food part standardize breakfast , lunch , dinner In good general health clinically significant relevant abnormality medical history physical examination include adequate renal function , alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5x Upper Limit Normal ( ULN ) QTcF &lt; 450 millisecond ( msec ) ; QTcF &lt; 480msec subject right Bundle Branch Block Females must postmenopausal Females hormone replacement therapy ( HRT ) must discontinue HRT allow confirmation postmenopausal status prior study enrollment Females &gt; 3 month postpartum undergone surgical sterilization procedure eligible participate consultation GSK Medical Monitor Parts B C ( Type 2 Diabetic Subjects ) All criterion mention Part A except Body Mass Index ( BMI ) 30.0 42.0 kg per m^2 Diagnosis T2D least 3 month , define American Diabetes Association All T2D subject must meet label recommendation metformin For Part B , subject must willing discontinue metformin replace daily liraglutide administer subcutaneous injection must meet label recommendation No personal history family history medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 History gastrointestinal disease , current chronic history liver disease , history serious , severe unstable physical psychiatric illness , significant cardiovascular disease , surgery weight loss gastrointestinal surgery within 3 month screen , document report eating disorder , uncontrolled hypertension , evidence systolic pressure &gt; 160 diastolic pressure &gt; 90 mmHg Positive test HIV , Hepatitis B , Hepatitis C Screening Subjects significant ECG abnormality For subject Part C ( continue metformin ) , history untreated pernicious anemia laboratory parameter suggestive subclinical megaloblastic anemia Presence symptom active infection Uncorrected Thyroid Dysfunction History chronic acute pancreatitis Currently diet lose weight include , limited , participation program design alter body weight within last 60 day unwilling maintain relatively consistent exercise pattern throughout study Current recent history ( within one year screening ) alcohol substance abuse Unable refrain use nonprescription drug Current participation another clinical study participation clinical study involve investigational drug within 30 day screen visit History sensitivity study medication , component thereof history drug allergy An employee sponsor study site member immediate family .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>metformin</keyword>
	<keyword>diabetes</keyword>
	<keyword>obesity</keyword>
	<keyword>liraglutide</keyword>
</DOC>